Signature Diagnostics Receives Extended Patent Protection for its Proteasome-Complex Inhibitors

09-Dec-2010 - Germany

Signature Diagnostics AG announced that the European Patent Office (EPO) has granted a new patent providing extended protection for drug molecules licensed by the company from the Technical University of Darmstadt. The new patent (EP 1858913) covers peptide-mimetics and their use as inhibitors of the human proteasome complex. The molecules have immediate application in a variety of indications, including cancer and inflammatory disease. The company is currently seeking cooperation partners for further development of these proteasome-inhibitor drug candidates.

"This patent further strengthens our strong intellectual property portfolio in key therapeutic areas such as cancer and inflammation," commented André Rosenthal, Chief Executive Officer of Signature Diagnostics. "We are committed to maximizing the patent protection for these drug candidates, as they are essential value-drivers for the company and its future partners."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances